

L30 ANSWER 2 OF 4 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 88-335630 [47] WPIDS
DNC C88-148450
TI Formulation applied in oral cavity - comprising pullalun and drug
component, pref. nifedipine.
DC A11 A96 B03 B07
PA (FUJW) FUJIMOTO SEIYAKU KK
CYC 1
PI JP63250319 A 881018 (8847)* 3 pp <--
ADT JP63250319 A 87JP-0083036 870406
PRAI 87JP-0083036 870406
IC A61K-007-16; A61K-009-00; A61K-047-00
AB JP63250319 A UPAB: 930923

The formulation applied in the oral cavity has bluran and a drug component
as an essential component.

USE/ADVANTAGE - The formulation is applied in the oral cavity mucous
membrane or the gingiva. (a) Formulation method is simple. (b) When the
tablet is applied in the oral cavity, the formulation sufficiently anchors
on the oral cavity mucous membrane or the gingiva. (c) When the
formulation is applied in the gingiva, the nifedipine (drug component) is
quickly absorbed into the gingiva from the oral cavity mucous membrane and
maintains stable nifedipine blood concn. for a long period. (d) When the
formulation is overdosed, the formulation is immediately and easily
removed. 0/0

L30 ANSWER 3 OF 4 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 88-335629 [47] WPIDS
DNC C88-148449
TI Formulation for oral cavity mucous membrane or gingiva - contg. bluran and
drug component e.g. lysozyme chloride as essential component.
DC A11 A96 B05 B07
PA (FUJW) FUJIMOTO SEIYAKU KK
CYC 1
PI JP63250318 A 881018 (8847)* 6 pp <--
ADT JP63250318 A 87JP-0083035 870406
PRAI 87JP-0083035 870406
IC A61K-007-16; A61K-009-00; A61K-047-00
AB JP63250318 A UPAB: 930923

Formulation applied in the oral cavity has bluran and a drug component as
an essential component. Pref. the drug component comprises: one or at
least two of lysozymes chloride, sodium azulene sulphonic acid,
buspyrrone, isosorbide nitrate, or tranexamic acid.

USE/ADVANTAGE - Used in oral cavity mucous membrane or the gingiva.
When the tablet is applied in the oral cavity, the formulation
sufficiently anchors on the membrane or the gingiva. The formulation has
affinity to the oral cavity. When the formulation is applied in the
gingiva, the drug component is quickly absorbed into the gingiva from the
membrane and maintains stable blood concn. for a long period. When the